Tatva Chintan Pharma Chem Limited — Investor Meet, 21-07-2026: Analysts/Institutional Investor Meet/Con. Call Updates

Tatva Chintan reported Q1 FY27 operating revenue of ₹167.1 Cr, up 43% YoY, with EBITDA at ₹32.3 Cr, up 86% YoY. Segment-wise, PTC, PASC, and SDA showed strong growth, while Electrolyte Salts were impacted by raw material delays.

Management highlighted Euro 7-driven SDA demand, growing PASC acceptance, and the successful qualification of its first semiconductor batch. The company has announced a board meeting on July 20, 2026, for a groundbreaking ceremony for a new ₹200 Cr multipurpose manufacturing facility, targeting ₹300 Cr revenue at peak. Tatva Chintan maintains FY27 guidance of 25-30% revenue growth and 20-22% EBITDA margins, anticipating 20-25% CAGR over 3-4 years.